MedPath

Efficacy of treatments for Japanese cedar pollinosis based on guideline -combined treatment ofleukotriene receptor antagonist with H1 receptor antagonists

Not Applicable
Conditions
Japanese cedar pollinosis
Registration Number
JPRN-UMIN000009647
Lead Sponsor
Okayama University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
100
Inclusion Criteria

Not provided

Exclusion Criteria

(1) concomitant sinonasal disease that could potentially affect the outcome of the trial (e.g., nasal polyps, rhinosinusitis, nasal septum deviation); (2) concomitant treatment for AR caused by allergens other than Japanese cedar/cypress pollen; (3) rhinitis medicamentosa and non-infectious, non-allergic rhinitis; (4) medication with anti-allergic drugs including H1RA, chromones, glucocorticoids and decongestants within 2 weeks of study initiation; (5) cedar pollen-specific immunotherapy; (6) sinonasal surgery including laser vaporization of inferior turbinates within 6 months;(7) concomittant uncontrolled asthma (8) hypersensitivity to INS and H1RA (9)systemic infection including mycosis; or (10) were pregnant and breastfeeding.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Symptoms and QO
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath